🇺🇸 FDA
Pipeline program

Buprenorphine/naloxone

NIDA-CTN-0027

Approved small_molecule completed

Quick answer

Buprenorphine/naloxone for Opiate-related Disorders is a Approved program (small_molecule) at BRIGHT MINDS BIOSCIENCES INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
BRIGHT MINDS BIOSCIENCES INC.
Indication
Opiate-related Disorders
Phase
Approved
Modality
small_molecule
Status
completed

Clinical trials